Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gemin X's high-five solution

Bcl-2 proteins have been cancer targets for at least a decade, based on the fact that cancer cells up-regulate Bcl-2 to evade apoptosis. However, companies haven't gotten very far with it, hindered by the challenges of inhibiting protein interactions. Gemin X Biotechnologies Inc.

Read the full 431 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers